This week Gilead Sciences slashed its 2020 revenue forecast, citing lower than expected demand for the COVID-19 drug Remdesivir. The company also said it was finding it difficult to predict sales of the drug, which is the only treatment in the U.S. that has been approved for patients who are hospitalized with COVID-19. The drug … Continue reading “Sales for Covid-19 Drug Remdesivir Fall Short Prompting Gilead to Cut 2020 Sales Outlook”
Tag: immunomedics
Biotech & Pharma
Gilead to Buy Cancer-drug Company Immunomedics for $21B
Over the weekend Gilead announced that it has agreed to purchase cancer-drug company Immunomedics for…
September 15, 2020